Earnings Call Summary | Dr Reddy's Laboratories Ltd(RDY.US) Q4 2024 Earnings Conference
Earnings Call Summary | Dr Reddy's Laboratories Ltd(RDY.US) Q4 2024 Earnings Conference
The following is a summary of the Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript:
以下是雷迪博士实验室有限公司（RDY）2024年第四季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
Dr. Reddy's reported full-year revenues of $3.3 billion, indicating an all-time high for the company.
Q4 revenues were around $850 million, showing a 12% YoY growth but a slight 2% sequential decline.
Dr. Reddy's exhibited double-digit growth in revenue, EBITDA, and PAT for the full year.
Both Q4 and FY2024 gross profit margin stood at 58.6%, an increase over the previous year.
SG&A spend for the year grew by 13% in line with business growth while R&D expense showed a YoY increase of 28%.
Full year profits after tax stood at $668 million, pointing towards a YoY growth of 24%.
雷迪博士报告的全年收入为33亿美元，这表明该公司的收入创历史新高。
第四季度收入约为8.5亿美元，同比增长12％，但连续略有下降2％。
雷迪博士全年收入、息税折旧摊销前利润和PAT均实现了两位数的增长。
第四季度和 FY2024 的毛利率均为58.6％，比上年有所增长。
该年度的销售和收购支出增长了13％，与业务增长一致，而研发费用同比增长了28％。
全年税后利润为6.68亿美元，同比增长24％。
Business Progress:
业务进展：
Dr. Reddy's marked its 40th year with expansions across multiple sectors of the pharmaceutical industry.
The company showed strong performance in the U.S market and made significant progress on future growth drivers.
Partnerships were formed with companies like Nestle and Sanofi, further indicating a focus on collaborations for future growth.
The company plans on 20+ new product launches in the U.S. market and anticipated double-digit growth in emerging markets such as China and India.
Investments in digitalization, and business expansions, as well as strengthening existing brands are being prioritized.
The company is focusing on biosimilars globally and plans to launch the generic version of Lumify this quarter.
Dr. Reddy's在制药行业的多个领域进行了扩张，标志着其成立40周年。
该公司在美国市场表现强劲，并在未来的增长驱动力方面取得了重大进展。
与雀巢和赛诺菲等公司建立了合作伙伴关系，这进一步表明了对未来增长的合作的关注。
该公司计划在美国市场推出20多款新产品，并预计中国和印度等新兴市场将实现两位数的增长。
投资数字化、业务扩张以及强化现有品牌是当务之急。
该公司在全球范围内专注于生物仿制药，并计划在本季度推出Lumify的仿制药。
More details: Dr Reddy's Laboratories Ltd IR
更多详情： 雷迪博士实验室有限公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。